Generic Yupelri Availability

Last updated on Apr 10, 2025.

Yupelri is a brand name of revefenacin, approved by the FDA in the following formulation(s):

YUPELRI (revefenacin - solution;inhalation)

Manufacturer: MYLAN IRELAND LTD
Approval date: November 9, 2018
Strength(s): 175MCG/3ML ^[RLD]

Is there a generic version of Yupelri available?

No. There is currently no therapeutically equivalent version of Yupelri available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yupelri. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Biphenyl compounds useful as muscarinic receptor antagonists
Patent 10,106,503
Issued: October 23, 2018
Inventor(s): Mammen Mathai & Ji YuHua & Mu YongQi & Husfeld Craig & Li Li
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC
This invention provides compounds of formula I:
Patent expiration dates:
- March 10, 2025
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 10,343,995
Issued: July 9, 2019
Inventor(s): Mammen Mathai & Ji YuHua & Mu YongQi & Husfeld Craig & Li Li
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC
This invention provides compounds of formula I:
Patent expiration dates:
- March 10, 2025
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Crystalline freebase forms of a biphenyl compound
Patent 10,550,081
Issued: February 4, 2020
Inventor(s): Woollam Grahame
Assignee(s): Theravance Biopharma R&D IP, LLC
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030
  ✓
  Drug substance
Crystalline freebase forms of a biphenyl compound
Patent 11,008,289
Issued: May 18, 2021
Inventor(s): Woollam Grahame
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 11,247,969
Issued: February 15, 2022
Inventor(s): Mammen; Mathai et al.
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001##
wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Drug product
Methods for treating chronic obstructive pulmonary disease
Patent 11,484,531
Issued: November 1, 2022
Inventor(s): Barnes; Christopher Noel et al.
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV.sub.1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV.sub.1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV.sub.1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.
Patent expiration dates:
- October 23, 2039
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Crystalline freebase forms of a biphenyl compound
Patent 11,691,948
Issued: July 4, 2023
Inventor(s): Woollam; Grahame
Assignee(s): Theravance Biopharma R&D IP, LLC (South San Francisco, CA)
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030
  ✓
  Drug product
Crystalline freebase forms of a biphenyl compound
Patent 11,858,898
Issued: January 2, 2024
Inventor(s): Woollam; Grahame
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  ✓
  Drug substance
  ✓
  Drug product
Methods for treating chronic obstructive pulmonary disease
Patent 12,048,692
Issued: July 30, 2024
Inventor(s): Barnes; Christopher Noel et al.
Assignee(s): THERA VANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV.sub.1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV.sub.1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV.sub.1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.
Patent expiration dates:
- August 29, 2039
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 7,288,657
Issued: October 30, 2007
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- October 31, 2028
  ✓
  Drug substance
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 7,491,736
Issued: February 17, 2009
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 7,521,041
Issued: April 21, 2009
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 7,550,595
Issued: June 23, 2009
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Drug product
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 7,585,879
Issued: September 8, 2009
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  ✓
  Drug substance
  ✓
  Drug product
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 7,910,608
Issued: March 22, 2011
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Drug substance
  ✓
  Drug product
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 8,034,946
Issued: October 11, 2011
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Patent expiration dates:
- March 10, 2025
  ✓
  Drug product
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 8,053,448
Issued: November 8, 2011
Inventor(s): Mammen; Mathai et al.
Assignee(s): Theravance, Inc. (South San Francisco, CA)
This invention provides methods of using compounds of formula Ib below to treat pulmonary disorders. ##STR00001## wherein: R.sup.4 is hydrogen or (1-4C)alkyl; q is 0, 1, or 2; R.sup.5 is independently selected from halo, (1-4C)alkyl, and (1-4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents; R.sup.7 is hydrogen or (1-4C)alkyl; or a pharmaceuticallly acceptable salt thereof.
Patent expiration dates:
- March 10, 2025
  ✓
  Patent use: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 8,273,894
Issued: September 25, 2012
Inventor(s): Mammen Mathai & Ji YuHua & Mu YongQi & Husfeld Craig & Li Li
Assignee(s): Theravance, Inc.
This invention provides compounds of formula I:
Patent expiration dates:
- March 10, 2025
  ✓
  Drug product
Crystalline freebase forms of a biphenyl compound
Patent 8,541,451
Issued: September 24, 2013
Inventor(s): Woollam Grahame
Assignee(s): Theravance, Inc.
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- August 25, 2031
  ✓
  Drug substance
Crystalline freebase forms of a biphenyl compound
Patent 9,765,028
Issued: September 19, 2017
Inventor(s): Woollam Grahame
Assignee(s): Theravance Biopharma R&D IP, LLC
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030
  ✓
  Drug substance

More about Yupelri (revefenacin)

Patient resources

Yupelri drug information

Professional resources

Related treatment guides

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

3 Reviews